| scholarly article | Q13442814 |
| P50 | author | Giuseppina Campisi | Q57011742 |
| Olga Di Fede | Q58354953 | ||
| Alberto Bedogni | Q73227178 | ||
| Giuseppe Pizzo | Q45733163 | ||
| P2093 | author name string | Stefano Fedele | |
| Vittorio Fusco | |||
| P2860 | cites work | Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? | Q46526002 |
| Osteonecrosis of the jaw and bisphosphonates | Q46586508 | ||
| Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw. | Q46691741 | ||
| Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors | Q46825147 | ||
| Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes | Q46870758 | ||
| Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases. | Q47277680 | ||
| Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment | Q47341487 | ||
| Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. | Q47727040 | ||
| Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up | Q48418714 | ||
| The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws | Q48672321 | ||
| Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. | Q51026901 | ||
| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 | ||
| A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws. | Q51401932 | ||
| Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. | Q51522929 | ||
| Supportive periodontal therapy. | Q51627085 | ||
| Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease. | Q53192323 | ||
| Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. | Q53434420 | ||
| The relationship of denosumab pharmacology and osteonecrosis of the jaws. | Q55056856 | ||
| Osteonecrosis of the Jaw After Zoledronic Acid and Denosumab Treatment | Q57010902 | ||
| A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma | Q57786339 | ||
| Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma | Q57904766 | ||
| The present and future role of bisphosphonates in the management of patients with breast cancer | Q24802100 | ||
| Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws | Q28240354 | ||
| Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials | Q28275006 | ||
| Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment | Q28278528 | ||
| Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis | Q28943549 | ||
| Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? | Q31041538 | ||
| Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology | Q31146923 | ||
| American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma | Q33285239 | ||
| Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? | Q33348613 | ||
| The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data | Q33431056 | ||
| Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). | Q33471543 | ||
| Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report | Q33898150 | ||
| Bisphosphonates cause osteonecrosis of the jaw-like disease in mice | Q33947252 | ||
| Bisphosphonates in oncology | Q34025747 | ||
| Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. | Q34035088 | ||
| Early surgical laser-assisted management of bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 101 treated sites with long-term follow-up. | Q34067434 | ||
| Hyperbaric oxygen therapy in the management of radiation-induced injury in the head and neck region: a review of the literature | Q34116948 | ||
| Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs). | Q34379676 | ||
| Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. | Q34381979 | ||
| Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis | Q34583705 | ||
| Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats | Q35155516 | ||
| Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. | Q35584343 | ||
| Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases | Q35762495 | ||
| Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy | Q36147087 | ||
| Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws? | Q36182848 | ||
| The dental implications of bisphosphonates and bone disease. | Q36370240 | ||
| Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. | Q36399335 | ||
| Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment | Q36496069 | ||
| Treatment strategies for skeletal complications of cancer | Q36592022 | ||
| Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study | Q36731919 | ||
| First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial | Q36804951 | ||
| Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study | Q43069291 | ||
| How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care | Q43076941 | ||
| Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment. | Q43110557 | ||
| Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer | Q43111250 | ||
| Bisphosphonate-related osteonecrosis of the jaw associated with dental implants | Q43121912 | ||
| Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. | Q43223892 | ||
| Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer | Q43242681 | ||
| Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. | Q43266784 | ||
| Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy | Q43472591 | ||
| Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic | Q43968160 | ||
| Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients | Q43973642 | ||
| Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol | Q44258310 | ||
| Osteonecrosis of the jaws induced by drugs other than bisphosphonates - a call to update terminology in light of new data | Q44358291 | ||
| Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction | Q44361728 | ||
| Bisphosphonate-related osteonecrosis of the jaw in four Nordic countries and an indication of under-reporting | Q44662910 | ||
| Ten years of alendronate treatment for osteoporosis in postmenopausal women | Q44973337 | ||
| Intravenous bisphosphonates and osteonecrosis | Q45050985 | ||
| Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. | Q45381957 | ||
| Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series | Q45581692 | ||
| Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan | Q45741123 | ||
| Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? | Q46115209 | ||
| Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone | Q46124362 | ||
| Tetracycline-guided debridement and cone beam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: a technical note | Q46236055 | ||
| Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome | Q46294584 | ||
| Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid | Q46438797 | ||
| Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. | Q46500802 | ||
| Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients | Q46523022 | ||
| Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals | Q36820652 | ||
| Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis | Q36860172 | ||
| Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel | Q36955961 | ||
| Biophosphonate-related osteonecrosis of the jaws | Q37043821 | ||
| Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. | Q37110398 | ||
| Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates | Q37179393 | ||
| Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. | Q37224099 | ||
| Osteonecrosis of the jaw: who gets it, and why? | Q37307232 | ||
| Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. | Q37345464 | ||
| The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network | Q37493951 | ||
| Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk | Q37547571 | ||
| Bisphosphonates and time to osteonecrosis development | Q37629434 | ||
| Surgical management of bisphosphonate induced osteonecrosis of the jaws | Q37656627 | ||
| Bisphosphonate-related osteonecrosis of the jaw presenting as a cutaneous dental sinus tract: a case report and review of the literature | Q37691757 | ||
| A systematic review of bisphosphonate osteonecrosis (BON) in cancer | Q37735736 | ||
| Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases | Q37761321 | ||
| Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. | Q37800179 | ||
| Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review | Q37809735 | ||
| Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs | Q37951255 | ||
| Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. | Q37993918 | ||
| Bisphosphonate-related osteonecrosis of the jaws--a review. | Q38004731 | ||
| The outcomes of conservative and surgical treatment of stage 2 bisphosphonate-related osteonecrosis of the jaws: a case series | Q38019194 | ||
| Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges | Q38019444 | ||
| Antiresorptives and osteonecrosis of the jaw. | Q38049751 | ||
| Emerging concepts in the management and treatment of osteonecrosis of the jaw. | Q38060390 | ||
| Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday | Q38062171 | ||
| Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series | Q38505485 | ||
| Inhibition of oral mucosal cell wound healing by bisphosphonates. | Q39132663 | ||
| Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome | Q39686090 | ||
| Radiographic Findings in Bisphosphonate-Treated Patients With Stage 0 Disease in the Absence of Bone Exposure | Q39845449 | ||
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Q41489196 | ||
| Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 | ||
| Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). | Q42325555 | ||
| Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. | Q42603658 | ||
| Breast-cancer adjuvant therapy with zoledronic acid | Q42620139 | ||
| Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 | ||
| Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw | Q42857395 | ||
| Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial | Q42878211 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | epidemiology | Q133805 |
| P304 | page(s) | 257-275 | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents | |
| P478 | volume | 10 |
| Q94372191 | Antiangiogenic agents and target therapy effect on ONJ occurrence: a pharmacovigilance monoinstitutional report |
| Q30239854 | Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. |
| Q48829569 | BRONJ in patients with rheumatoid arthritis: a multicenter case series. |
| Q55407354 | Bevacizumab - related osteonecrosis of jaw in a rectal cancer patient never treated with bisphosphonates. |
| Q55489059 | Bisphosphonate related osteonecrosis of the jaws: case report in patient with multiple myeloma. |
| Q36604330 | Chemical and Radiation-Associated Jaw Lesions |
| Q28084019 | Chemotherapy- and irradiation-induced bone loss in adults with solid tumors |
| Q38716842 | Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature |
| Q58766046 | Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study |
| Q96962756 | Conservative non-surgical management in medication related osteonecrosis of the jaw: A retrospective study |
| Q33865551 | Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients |
| Q55555000 | Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients? |
| Q55094789 | Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. |
| Q61811480 | Denosumab Related Osteonecrosis of Jaw: a Case Report |
| Q38660112 | Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review |
| Q47251973 | Denosumab-related osteonecrosis of the jaw: A retrospective study. |
| Q39013177 | Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures |
| Q91675370 | Dental care for patients taking antiresorptive drugs: a literature review |
| Q37713115 | Dental extraction following zoledronate, induces osteonecrosis in rat's jaw. |
| Q53409567 | Dramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis, and dental implant removal. |
| Q85476262 | Jaw problems: Update on ARONJ |
| Q46413278 | Metachronous sites of osteonecrosis of jaw (ONJ) in all four quadrants of maxilla bones and mandible: a case report. |
| Q57053962 | Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw |
| Q55426041 | Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review. |
| Q94372167 | ONJ (osteonecrosis of jaw) in breast cancer patients: effect of preventive measures in a mono institutional experience |
| Q46007868 | ONJ (osteonecrosis of jaw) in osteoporosis patients after ibandronate treatment: report of two cases. |
| Q94358588 | Ostenecrosis of Jaw (ONJ) Related to Bisphosphonates and other Drugs: Prevention, Diagnosis, Drug Surveillance, Treatment. Update 2014 Alessandria, Sabato 10 Maggio 2014 |
| Q94372111 | Osteonecrosis of jaw (ONJ) 2003–2014: analysis of literature reporting |
| Q94372117 | Osteonecrosis of jaw (ONJ) in Italy: 2014 update of role of Italian patients, physicians, dentists, researchers |
| Q46041564 | Osteonecrosis of jaw (ONJ) in prostate cancer patients: report of a monoinstitutional experience |
| Q38807483 | Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology |
| Q52643968 | Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition. |
| Q55332559 | Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature. |
| Q55346257 | Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures. |
| Q37525339 | Osteonecrosis of the jaw associated with ziv-aflibercept |
| Q55400309 | Osteonecrosis of the jaws in cancer patients with bone metastasis: a preliminary analysis of a single center prevention experience. |
| Q34512454 | Position paper on medication-related osteonecrosis of the jaw (MRONJ) |
| Q35066955 | Side effects of bone-targeted therapies in advanced breast cancer |
| Q50053219 | Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol |
| Q57300255 | The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention |
| Q38776007 | Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. |
Search more.